文献速递抗栓抗凝管理药物不良反应与药物警戒

靶向特异性口服抗凝药逆转剂的作用

Role of agents for reversing the effects of target-specific oral anticoagulants.
PubMed 文献 · Am J Health Syst Pharm · 2016-11-28

本文综述了靶向特异性口服抗凝药(TSOAC)逆转剂的临床数据。Idarucizumab 已于 2015 年 10 月获 FDA 批准用于逆转达比加群的抗凝作用,andexanet alfa 和 ciraparantag 处于不同临床开发阶段。这些逆转剂在临床试验中耐受性良好,为 TSOAC 相关危及生命出血或紧急手术提供了潜在治疗选择。

要点

  • Idarucizumab 获 FDA 批准用于逆转达比加群抗凝效应。
  • Andexanet alfa 和 ciraparantag 可逆转口服直接 Xa 因子抑制剂。
  • Idarucizumab 和 andexanet alfa 在给药后数分钟内产生逆转效应。

核心结论

  • Idarucizumab 及其他 TSOAC 逆转剂为危及生命或不可控的 TSOAC 相关出血或紧急手术提供了潜在一致有效的治疗管理选择。

研究设计与样本

  • 本文为综述,总结了已获 FDA 批准或处于开发阶段的 TSOAC 逆转剂的现有临床数据。

主要发现

  • Idarucizumab 和 andexanet alfa 可在给药后数分钟内产生抗凝逆转效应。
  • Ciraparantag 在 10 分钟或更短时间内将全血凝血时间降至基线值的 10% 以内,并在 10-30 分钟内恢复至基线止血状态。
  • TSOAC 逆转剂在临床试验中通常耐受性良好。

关键数值与推荐

  • Idarucizumab 于 2015 年 10 月获 FDA 批准,用于口服直接凝血酶抑制剂达比加群的逆转。
  • Andexanet alfa 和 ciraparantag 是口服直接 Xa 因子抑制剂的潜在逆转剂,处于不同临床开发阶段。

临床怎么用

  • 对于使用 TSOAC 的患者,发生危及生命或不可控出血或需紧急手术时,可考虑使用特异性逆转剂。

局限性

  • 新鲜冰冻血浆、凝血酶原复合物浓缩物和重组凝血因子 VIIa 等非特异性治疗用于 TSOAC 相关出血管理时结果不一致。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The available clinical data on target-specific oral anticoagulant (TSOAC) reversal agents that are currently in development or have been approved by the Food and Drug Administration (FDA) are reviewed. SUMMARY: The development of TSOACs such as dabigatran, rivaroxaban, edoxaban, and apixaban has presented benefits and new challenges. One of the main challenges associated with the use of TSOACs is the lack of suitable agent-specific reversal agents. Several treatment options for the management of life-threatening bleeding events associated with TSOAC use, such as fresh frozen plasma, prothrombin complex concentrates, and recombinant coagulation factor VIIa, have been used, with inconsistent results. Currently, two potential reversal agents for oral direct factor Xa inhibitors (andexanet alfa and ciraparantag) are at various stages of clinical development. Idarucizumab, a reversal agent for the oral direct thrombin inhibitor dabigatran, was approved by FDA in October 2015. Idarucizumab and andexanet alfa have been reported to produce anticoagulation reversal effects within minutes of administration. Ciraparantag was demonstrated to decrease whole blood clotting time to within 10% of baseline values in 10 minutes or less, with a return to baseline hemostasis in 10-30 minutes. TSOAC reversal agents have been generally well tolerated in clinical trials. CONCLUSION: Idarucizumab and other TSOAC reversal agents, such as andexanet alfa and ciraparantag, present the potential for consistent and effective treatment and management options when life-threatening or uncontrolled TSOAC-associated bleeding occurs or when emergency surgery is warranted in patients using TSOACs.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Riley TR, Gauthier-Lewis ML, Sanchez CK, et al. Role of agents for reversing the effects of target-specific oral anticoagulants. Am J Health Syst Pharm. 2016. PMID: 27895055. doi:10.2146/ajhp150810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。